Thoracic Malignancies: A Review of the Latest Evidence
Great therapeutic strides have been made for non-small cell lung cancer (NSCLC).
In this CME, renowned specialists from multidisciplinary backgrounds will present innovative treatment modalities that include medical, surgical and radiation oncology, pulmonology, and radiologic options.
The conference explores new care paradigms for early-stage disease, including the CheckMate-816 trial that combines immunotherapy with chemotherapy, and a discussion of eligibility through molecular and PD-L1 testing. Targeted therapies for EGFR mutations or ALK translocations, and EGFR-targeted therapy for locally advanced disease will also be discussed.
OBJECTIVES:
- Treat patients with the right targeted therapy
- Offer neoadjuvant chemo-IO to the appropriate patients
- Discuss adjuvant immunotherapy
PROGRAM DIRECTORS:
Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology
Professor, Department of Hematology/Oncology
Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Fox Chase Cancer Center
Joseph Friedberg, MD, FACS
Thoracic Surgeon-in-Chief, Temple University Health System
Vice Chair, Surgical Services, Department of Thoracic Medicine and Surgery
Co-Director, Temple-Fox Chase Cancer Center Mesothelioma and Pleural Disease Program
Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University
INTENDED AUDIENCE:
Medical, surgical and radiation oncologists; thoracic and general surgeons; pulmonologists; gastroenterologists; pathologists; radiologists; fellows/residents/students; nurses; physician assistants; pharmacists; researchers; and advanced practice clinicians involved in the management of patients with lung cancer and thoracic malignancies.
ACCREDITATION STATEMENT:
The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians. Fox Chase Cancer Center is approved as a provider of nursing continuing professional development by the Pennsylvania State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
DESIGNATION STATEMENT:
The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity. Fox Chase Cancer Center designates this live activity for a maximum of 5.5 Hour(s) NCPD (ANCC Contact Hours). Participants should claim only the credit commensurate with the extent of their participation in the activity.
PLANNING COMMITTEE:
Moshe Chasky, MD, FACP
Medical Oncology & Hematology, Alliance Cancer Specialists
Melissa Culligan, RN, MS, PhD
Candidate Director of Thoracic Surgery Research at Temple Health
Co-Director, Temple-Fox Chase Cancer Center
Mesothelioma and Pleural Disease Program
John Leighton, MD
Medical Oncology & Hematology, Jefferson Health
Anjana Ranganathan, MD
Medical Oncology & Hematology, Alliance Cancer Specialists